Home Cart Sign in  
Chemical Structure| 363600-92-4 Chemical Structure| 363600-92-4
Chemical Structure| 363600-92-4

C29

CAS No.: 363600-92-4

C29 is a Toll-like receptor 2 (TLR2) inhibitor. C29 blocks hTLR2/1 and hTLR2/6 signaling with IC50 values of 19.7 μM and 37.6 μM, respectively. C29 has anti-inflammatory and immunomodulatory effects and can be used in research on rheumatic diseases and inflammation-related studies.

Synonyms: TLR2-IN-C29

4.5 *For Research Use Only !

Cat. No.: A134430 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇî¶ÊÊ Inquiry Inquiry
5mg ł§ó¶ÊÊ Inquiry Inquiry
10mg łÍó¶ÊÊ Inquiry Inquiry
50mg łÇËͶÊÊ Inquiry Inquiry
100mg łÇóó¶ÊÊ Inquiry Inquiry
250mg łËîď¶ÊÊ Inquiry Inquiry
1g łďď˶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇî¶ÊÊ

  • 5mg

    ł§ó¶ÊÊ

  • 10mg

    łÍó¶ÊÊ

  • 50mg

    łÇËͶÊÊ

  • 100mg

    łÇóó¶ÊÊ

  • 250mg

    łËîď¶ÊÊ

  • 1g

    łďď˶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of C29

CAS No. :363600-92-4
Formula : C16H15NO4
M.W : 285.29
SMILES Code : O=C(O)C1=CC=CC(/N=C/C2=CC=CC(OC)=C2O)=C1C
Synonyms :
TLR2-IN-C29
MDL No. :MFCD01248566
InChI Key :WTGMGRFVBFDHGQ-UHFFFAOYSA-N
Pubchem ID :3579893

Safety of C29

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of C29

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
786-O cells 2.5 µM 24 h To evaluate the stability of C29 in cells, results showed that C29 is highly stable in cells PMC6691587
HuVEC cells 2.5 µM 1 h To evaluate the effect of C29 on CXCR1 or CXCR2 levels at the plasma membrane of HuVEC cells stimulated with CXCL7 or CXCL8, results showed that C29 prevented CXCL7/8-dependent internalization of their receptors PMC6691587
HepG2 cells different doses To evaluate the effect of C29 on the mRNA levels of ESRRα, ApoB, MTTP, and PLA2G12B in HepG2 cells, results showed that C29 dose-dependently suppressed the expression of these genes. PMC7532682
BV-2 microglial cells 100 µM 60 min C29, as a TLR2 inhibitor, was used to study the effects of P. gingivalis-LPS and E. coli-LPS on the immuno-inflammatory response in BV-2 microglial cells. The results showed that C29 could reverse the LPS-induced upregulation of TLR2 and inflammatory factors. PMC8012810
RAW 264.7 murine macrophages 100 μM 1 h Inhibited the TLR2/MyD88/NF-κB signaling pathway, reducing M1 macrophage polarization and cytokine production PMC11437915
LS174T cells 50 µM 6 h C29 significantly abolished the induction of TFF3 by EcN EVs and prevented the downregulation of miR7-5p PMC10255446
BV-2 cells 100 μM 4, 12, 24 h C29 significantly blocked the upregulation of COX-2 protein levels caused by LTA treatment. PMC11611525
THP1 cells 150 µM 1 h Inhibited TLR2, blocking S2 protein-induced inflammatory response PMC8709575
Calu3 cells 150 µM 1 h Inhibited TLR2, blocking S2 protein-induced inflammatory response PMC8709575

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
nude mice RCC xenograft model oral gavage 50 mg/kg five times a week for four weeks To evaluate the effect of C29 on RCC tumor growth, results showed that C29 significantly reduced tumor volume and weight PMC6691587
C57BL/6 mice LPS-induced cognitive impairment model Oral 1 × 10^9 CFU/mouse Once daily for 5 days C29 significantly alleviated LPS-induced cognitive impairment, increased spontaneous alternation in the Y-maze task and exploration in the NOR task, suppressed NF-κB activation and inflammatory cytokine expression in the hippocampus, and increased BDNF expression. PMC8465226
mice HFD-induced NAFLD model intragastric administration 30 mg/kg once a day for 3 weeks To evaluate the effect of C29 on HFD-induced NAFLD model, results showed that C29 exacerbated hepatic steatosis and reduced plasma TG and ApoB levels as well as hepatic VLDL-TG secretion rate. PMC7532682

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.51mL

0.70mL

0.35mL

17.53mL

3.51mL

1.75mL

35.05mL

7.01mL

3.51mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories